Based on the results of these phase 2 trials, a phase 3 randomized clinical trial was conducted to compare AZA + eprenetapopt to AZA monotherapy in TP53 MDS patients (clinicaltrials.gov NCT: NCT03745716). The gene discussed is TP53; the disease is myelodysplastic syndrome.